CytoSorbents Corp (CTSO) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Fourth Quarter Product Revenue: $9.2 million, a 25% increase compared to the prior year.
Full Year Product Revenue: $35.6 million, representing 15% year-over-year growth.
Core Product Sales: $35.6 million in 2024.
Gross Margin: 71% for both the quarter and the full year.
Operating Expenses: Decreased 30% year-over-year to $10.2 million in Q4.
Operating Loss: Improved 61% year-over-year to $3.7 million in Q4.
Adjusted EBITDA Loss: Improved by 70% to $2.4 million in Q4.
Net Loss: $7.5 million or $0.14 per share in Q4.
Adjusted Net Loss: Improved to $1.7 million or $0.03 per share in Q4.
Cash and Cash Equivalents: $9.8 million as of December 31, 2024; pro forma cash position approximately $17 million.
Debt Facility: $20 million with Avenue Capital Group, consummated in June 2024.
Shareholder Rights Offering: Raised total net proceeds of $7.3 million.
Warning! GuruFocus has detected 5 Warning Signs with CTSO.
Release Date: March 31, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
CytoSorbents Corp (NASDAQ:CTSO) reported a 25% increase in fourth-quarter product revenue, reaching $9.2 million, and a 15% year-over-year growth in full-year product revenue for 2024.
The company's core product, CytoSorb, has been utilized in over 270,000 devices across more than 70 countries, driving significant international sales.
CytoSorbents Corp (NASDAQ:CTSO) maintained a healthy product gross margin of 71%, reflecting the strength of their business model.
The company strengthened its financial position with a $20 million debt facility and a successful shareholder rights offering, increasing liquidity by $12.3 million.
CytoSorbents Corp (NASDAQ:CTSO) is actively preparing for the potential commercial launch of DrugSorb-ATR in the US and Canada, with a total addressable market opportunity of $300 million, potentially growing to over a billion dollars.
CytoSorbents Corp (NASDAQ:CTSO) experienced flat growth in direct sales in Germany, which is their largest market, for the second consecutive year.
The company identified misstatements in inventory and non-cash stock compensation, leading to a restatement of their 2023 and 2024 financial reports.
There is a material weakness in CytoSorbents Corp (NASDAQ:CTSO)'s internal controls over financial reporting, which they aim to remediate during the current calendar year.
The reorganization of the sales team in Germany is expected to cause short-term disruption, resulting in modestly lower product sales in the first quarter of 2025.
CytoSorbents Corp (NASDAQ:CTSO) anticipates that the DrugSorb-ATR business will not be immediately profitable upon launch due to initial investments in commercial capabilities.
Q: Have you seen any impacts from the new US administration on the regulatory process for DrugSorb, and what gives you confidence in clearance by year-end? A: Although there have been cuts to HHS, including the FDA, these cuts are not targeting review personnel. This gives us confidence in the timeline for clearance by year-end. - Phillip Chan, CEO
Q: What are the key things you'll be looking for during the controlled launch of DrugSorb before a full commercial launch? A: We aim to learn how to get into hospitals, get onto their lists, and get ordered. We want to understand how quickly we can get through VA committees and how surgeons integrate the product into their usage patterns. This will help us titrate the launch effectively. - Peter Mariani, CFO
Q: What kind of commercial organization size might you need to fully commercialize in the US? A: We anticipate a sales force of 15 to 25, potentially larger over time. We aim to establish sticky accounts early and grow usage across multiple surgeons. We may also use distributors in certain regions. - Peter Mariani, CFO
Q: What were the main growth drivers for sales outside Germany, and why did they not apply to the German market? A: Growth outside Germany was driven by strong adoption in specific applications and successful reimbursement strategies. In Germany, issues like post-COVID challenges and hospital reforms have impacted growth. We are reorganizing our sales approach to address these challenges. - Phillip Chan, CEO
Q: What metrics do you need to hit to reach near cash break-even in the core business by the end of the year? A: We need continued revenue growth and maintaining 70%+ gross margins. Driving efficiencies and reducing cash burn are also crucial to achieving cash flow break-even in the core business, allowing investment in DrugSorb's launch. - Peter Mariani, CFO
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Why CrowdStrike (CRWD) Stock Is Falling Today
Shares of cybersecurity company CrowdStrike (NASDAQ:CRWD) fell 5.5% in the afternoon session after the company reported mixed first quarter 2025 (Q1 FY-26) results: its revenue guidance for next quarter slightly missed and its full-year revenue guidance was just in line with Wall Street's estimates. On the other hand, CrowdStrike beat convincingly on operating profit. Looking ahead, guidance was solid. The company's EPS guidance for next quarter topped analysts' expectations, and its full-year EPS guidance slightly exceeded Wall Street's estimates as well. Overall, this was a mixed quarter and not enough for the high expectations around the stock (as evidenced by the 52-week high right before reporting and a 40+% stock price appreciation year-to-date before the print). The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy CrowdStrike? Access our full analysis report here, it's free. CrowdStrike's shares are very volatile and have had 20 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 11 months ago when the stock dropped 14.7% following a global technology outage. The outage was caused by a faulty update deployed by CrowdStrike to computers running the Microsoft Windows operating system. CrowdStrike clarified that the issue wasn't caused by "a security incident or cyberattack." CEO George Kurtz noted on the social media platform X (formerly called Twitter) that "the issue has been identified, isolated, and a fix has been deployed." However, the issue had far-reaching consequences, affecting systems in industries delivering critical services, including hospitals, banks, and airports. CRWD stock's decline suggested markets might be struggling to understand the long-term implications of the issue, especially as it relates to CrowdStrike maintaining its dominance in the highly competitive cybersecurity space, which often permits little to no room for mistakes. Wedbush analyst Dan Ives provided insights on how this might play out, adding, "It could create opportunity for some competitive displacements, but this will take time to determine the path of CIOs and companies looking ahead and related legal actions related to this outage." CrowdStrike is up 33% since the beginning of the year, and at $461.84 per share, it is trading close to its 52-week high of $488.76 from June 2025. Investors who bought $1,000 worth of CrowdStrike's shares 5 years ago would now be looking at an investment worth $4,812. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Yahoo
20 minutes ago
- Yahoo
Apple Faces Downgrade on Valuation Fears and AI Competition
June 4 - Apple (NASDAQ:AAPL) shares were downgraded by Needham to "Hold" from "Buy" on Wednesday, citing valuation concerns and rising threats from tech competitors. Analysts said the stock's forward price-to-earnings ratio for 2026 stands above 26 times, a level they view as stretched relative to earnings prospects. The firm noted that 21 analysts have revised earnings estimates lower in recent weeks, while Apple's revenue growth remains under 5%. Warning! GuruFocus has detected 9 Warning Signs with CRWV. Needham flagged growing risks to Apple's near-term earnings, especially from companies challenging the so-called platform tax. The firm also pointed to emerging generative AI trends that could fuel demand for alternative hardware, which may pose risks to Apple's iOS ecosystem. A catalyst such as a new iPhone cycle would be needed to re-rate the stock, the firm said, though they don't expect that within the next year. Needham suggested a more attractive entry point might be between $170 and $180. Other brokers remain bullish. Evercore ISI kept an Outperform rating with a $250 price target, citing strong App Store revenue in May. JPMorgan maintained an Overweight stance with a $240 target, anticipating new AI features at next week's WWDC. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Why CoreWeave Rocketed 170% in May
CoreWeave rallied in May off of the April "liberation day" bottom. The company held its first earnings release, beating expectations and raising guidance. Nvidia disclosed that it raised its investment in the company. 10 stocks we like better than CoreWeave › Shares of CoreWeave (NASDAQ: CRWV) rocketed 169.5% in May, according to data from S&P Global Market Intelligence. CoreWeave had a busy month, not only recovering from April's "Liberation Day" along with the rest of the sector, but also holding its first earnings report since its March 28 initial public offering (IPO). Additionally, key customer and supplier Nvidia (NASDAQ: NVDA) disclosed that it had increased its investment in the company. Virtually all technology stocks and artificial intelligence (AI) stocks recovered in a big way after May 12, when the U.S. and China ratcheted down their mutual tariffs for 90 days in order to let trade talks proceed. The sky-high China tariffs had been at the heart of the worries over President Trump's tariff war, which had especially weighed on the semiconductor and AI sectors. Shortly after the rollback of China tariffs, CoreWeave also held its first-ever earnings release. In that release, CoreWeave beat revenue expectations handily. And while earnings per share missed by a lot, that was caused by one-time stock compensation costs associated with the IPO. Moreover, CoreWeave raised its revenue guidance for the year well above analyst estimates, although it also increased its outlook for capital expenditures. While investors had something of a mixed reaction to earnings, most Wall Street analysts raised their price targets afterward. But just days later, CoreWeave saw a massive spike in its stock after it was revealed that AI chip darling Nvidia had increased its investment in the company. That was followed by even larger analyst price target increases the following week. Not only did CoreWeave have a monster month of May, but the stock has also surged to begin June, following news of a 15-year, $7 billion data center expansion agreement with data center operator Applied Digital (NASDAQ: APLD). Given the massive spike in the stock price, there's a degree of meme stock momentum right now in CoreWeave. So investors should be careful with the stock at this valuation, which currently sits at about 15 times this year's revenue outlook. That's a high price for a stock with high investment needs and some substantial risks. One concern is that CoreWeave has to invest substantial amounts in fixed assets ahead of receiving revenues from its contracts. However, it appears investors are encouraged by the more aggressive growth outlook and willing to look past upfront investment needs in fixed costs that will probably require CoreWeave to raise more capital. Another risk that concerns me is the company's circular relationship with Nvidia, which is both a customer and, obviously, a key supplier. While AI demand and demand for Nvidia chips appears quite strong for now, should either demand ever slow down, CoreWeave could run into problems. Before you buy stock in CoreWeave, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CoreWeave wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Billy Duberstein and/or his clients have no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy. Why CoreWeave Rocketed 170% in May was originally published by The Motley Fool
